video
Thư viện
Tài trợ
Đừng đòi hỏi chúng tôi như trước
28 Feb, 2020
các công ty dược lớn nói rõ rằng, cách thức chính phủ huy động họ những lúc khẩn cấp, sản xuất vaccine này hay mặt hàng kia khiến phá vỡ hoạt động thường ngày của họ, và không bền vững,
-----
GSK has made a corporate decision that while it wants to help in public health emergencies (tình huống khẩn cấp về y tế công), it cannot continue to do so in the way it has in the past. Sanofi Pasteur has said its attempt to respond to Zika has served only to mar (làm hư, làm hỏng, làm hại) the company’s reputation (danh tiếng của công ty). Merck has said while it is committed to getting its Ebola vaccine across the finish line it will not try to develop a vaccine that protects against other strains of Ebola and the related Marburg virus.
Drug makers “have very clearly articulated that … the current way of approaching this — to call them during an emergency and demand that they do this and that they reallocate resources (tái phân bổ nguồn lực), disrupt (phá vỡ) their daily operations (hoạt động thường ngày) in order to respond to these events — is completely unsustainable,” said Richard Hatchett, CEO of CEPI, an organization set up after the Ebola crisis to fund early-stage development of vaccines to protect against emerging disease threats.
Hatchett and others who plan for disease emergencies worry that, without the involvement of these types of companies, there will be no emergency response vaccines.
Bài trước: Nước Mỹ khiêm tốn
Tags: health
Russia has highly developed biology programs, not based on profit concerns.
Sounds like the sort of position that a state capacity libertarian would have no problem getting behind, as patents are a government granted monopoly, whose sole justification is that it serves the public good, not the goal of making the rich richer.
Providing an incentive for innovation is exactly the "public good" that the patent system exists for.
Yes, this space is messed up and needs fixing. I think the biggest problems are:
1) the U.S. health insurance system preventing a functioning market in which competition and cost/benefit calculations lower prices (I would include in this Medicare and Medicaid being forbidden to negotiate on drug prices).
2) Drug development getting far too expensive due to excess regulation.
Prior to patent laws changing back, there was no great boon in drugs discovered. Most of what was found in that era was just a biological extract, often hormones, and required exceedingly little R&D. Of course the quality control was terrible and people routinely died from impure preparations, but what are a few dead kids to the system?
After the patent system we started getting targeted drugs aimed at specific illnesses. Good luck waiting around for serendipity to show you compounds that help with anything aside from infections.
There have been plenty of places that do not respect international patents or where state enforcement is weak. None pull above their weight in drug discovery. Heck, even places with Beveridge health systems typically punch below their weight for drug R&D.
At the end of the day, you get what you pay for. Drug discovery and production should be highly profitable, we want it soaking up capital faster than social media "innovation".